Ophirex is a technology company.
Ophirex has raised $37.0M across 1 funding round.
Ophirex has raised $37.0M in total across 1 funding round.
Ophirex is a public benefit biotechnology company headquartered in Corte Madera, California, dedicated to global health by developing affordable, accessible treatments for snakebite envenoming and related life-threatening bites, stings, and conditions.[1][2][3] The company is advancing varespladib, a small-molecule inhibitor of secretory phospholipase 2 (sPLA2) enzymes in snake venom, designed for oral or IV administration to reverse paralysis, restore blood clotting, and improve outcomes even with delayed use.[2] With under 25 employees and revenue below $5 million, Ophirex has secured $37 million in total funding, including a recent Series B round, and serves snakebite victims worldwide—particularly in under-resourced areas—addressing a crisis affecting over 450 venomous snake species where fewer than half have matching antivenoms.[1][2][4] Its growth momentum includes preclinical successes, U.S. Department of Defense grants, a Wellcome Trust award, and explicit endorsement in the WHO's 2019 snakebite roadmap.[2][4]
Ophirex emerged from a commitment to tackle snakebite as a neglected tropical disease, gaining initial traction through backing from family, friends, philanthropists, and public health supporters, alongside contributions from scientific and medical experts.[4] As a Delaware-registered public benefit corporation, it balances shareholder returns with its mission to deliver life-saving treatments for envenoming, especially in resource-poor regions.[1][3][4] Key early momentum came from preclinical data on varespladib—a compound with an established safety profile from prior studies—demonstrating potent, broad-spectrum inhibition of venom sPLA2 enzymes.[2] Pivotal recognition arrived in 2019 when the WHO Snakebite Envenoming Working Group cited varespladib for accelerated development in its roadmap to halve envenoming deaths and disabilities by 2030, amid rising risks from population growth and climate change.[4]
Ophirex stands out in snakebite treatment through these key advantages:
Ophirex rides the wave of innovation in neglected tropical diseases (NTDs), where the WHO classified snakebite envenoming in 2017 due to its 100,000+ annual deaths—rivaling other NTDs combined—and escalating risks from human-snake habitat overlap driven by climate change and population growth.[4] Biotech advances in small-molecule venom inhibitors address market failures of traditional antivenoms, which rely on labor-intensive animal-derived processes, cold storage, and limited matching.[2] Favorable forces include philanthropic funding, government grants, and WHO roadmaps prioritizing next-generation therapies like varespladib.[2][4] By pioneering oral, broad-spectrum treatments, Ophirex influences the ecosystem, potentially expanding to veterinary uses and other sPLA2-linked conditions, while lowering barriers for global access in low-resource settings.[2][4]
Ophirex is poised to advance varespladib into human and veterinary clinical trials, leveraging its $37 million Series B to validate broad-spectrum efficacy and safety for worldwide rollout.[1][2] Trends like AI-accelerated drug repurposing, climate-driven envenoming surges, and NTD investment will propel its trajectory, with potential expansions to additional venom targets or formulations.[2][4] Its influence could evolve from niche innovator to ecosystem shaper, delivering the affordable oral antidote that redefines snakebite care—fulfilling its public benefit promise amid a crisis demanding global solutions.[2][4]
Ophirex has raised $37.0M in total across 1 funding round.
Ophirex's investors include Adjuvant Capital, Charles Petty.
Ophirex has raised $37.0M across 1 funding round. Most recently, it raised $37.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $37.0M Series B | Adjuvant Capital, Charles Petty |